Mineralys Therapeutics, Inc. develops medicines for hypertension and related comorbidities driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for hypertension, chronic kidney disease, obstructive sleep apnea and other aldosterone-related conditions.
Mineralys news commonly covers lorundrostat clinical data, FDA regulatory updates, New Drug Application developments, and corporate updates tied to clinical and regulatory funding. Other recurring announcements include quarterly financial results, health care conference participation, executive appointments, and employee equity inducement awards under Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics (MLYS) reported long-term lorundrostat trial results showing a 17.8 mmHg reduction in automated office systolic blood pressure.
In the Transform-HTN open-label extension, the reduction was measured at Week 48 against Launch-HTN baseline in 504 participants; 56.0% reached systolic pressure below 130 mmHg. Participants continued existing blood pressure medicines during the additional 36 weeks of treatment. Of 632 enrolled participants, 583 (92%) completed 48 weeks of follow-up.
Serious adverse events affected 27 participants (4.3%); investigators considered two treatment-related. Adverse events led 37 participants (5.9%) to discontinue treatment. The company reported no new clinically relevant safety findings compared with Launch-HTN. FDA review for hypertension treatment alongside other antihypertensive drugs is underway, with a December 22, 2026 target decision date.
Mineralys Therapeutics (Nasdaq: MLYS) granted stock options and restricted stock units to a new non-executive employee on November 3, 2026.
The awards cover 14,880 option shares and 11,160 restricted stock units under the 2025 Employment Inducement Incentive Award Plan. Both awards vest over four years, subject to continued service, with a vesting commencement date of November 2, 2026. The grants were employment inducements made in accordance with Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics (MLYS) reported third-quarter financial results while preparing for a potential commercial launch of its hypertension drug lorundrostat. The FDA review has a December 22, 2026 target decision date; approval remains pending. An expanded medical affairs team and sales force are in place.
In Launch-HTN, 46% of participants receiving 50 mg reached office systolic blood pressure below 130 mmHg at Week 12. Explore-OSA showed lower morning blood pressure but no measurable change in sleep apnea frequency. Third-quarter net loss widened to $57.328 million from $36.932 million a year earlier as administrative expenses rose, while research expenses fell. Cash, cash equivalents and investments totaled $624.672 million at September 30, versus $656.635 million at December 31, 2025. Mineralys expects its funds to support planned operations, including launch, into 2028.
Mineralys Therapeutics (Nasdaq: MLYS) announced that senior management will participate in fireside chats at three upcoming healthcare investor conferences.
The sessions are scheduled for Guggenheim on November 10, 2026, at 2:30pm ET; Stifel on November 12 at 8:40am ET; and the 9th Annual Evercore Healthcare Conference on December 1 at 1:45pm ET. Live webcasts and archives will be available through the company’s Investor Relations News & Events page.
Mineralys Therapeutics (MLYS) will report third-quarter 2026 financial results after markets close on November 4, 2026, and host a conference call. The results cover the quarter ended September 30, 2026. The call begins at 4:30 p.m. ET, with a live webcast available through the company website’s Investors section under News & Events.
Mineralys Therapeutics (Nasdaq: MLYS) announced publication of its Phase 2 Explore-CKD trial results for lorundrostat in Kidney International.
The trial randomized 59 participants with uncontrolled hypertension, stage 1 to 3b chronic kidney disease and albuminuria, or albumin loss in urine. Lorundrostat 25 mg once daily, added to an SGLT2 inhibitor, met the primary endpoint at four weeks: automated office systolic blood pressure fell 9.3 mmHg versus 1.8 mmHg with placebo, a 7.5 mmHg placebo-adjusted reduction (p=0.0024). The urinary albumin-to-creatinine ratio, a measure of kidney protein loss, fell 25.6% versus placebo (p=0.0015). Serum aldosterone decreased 41.5% with lorundrostat versus a 1.8% increase with placebo.
The company expects longer-term data shortly from Explore-CKD participants enrolled in the Transform-HTN open-label extension, where treatment is known to participants and investigators.
Mineralys Therapeutics (MLYS) presented new Phase 3 Launch-HTN data showing lorundrostat reduced blood pressure in participants with and without chronic kidney disease (CKD).
At week 12, placebo-adjusted systolic blood pressure reductions were 9.6 mmHg with CKD and 12.2 mmHg without CKD, both statistically significant. Reductions were consistent across CKD Stages 1–3. Among participants with CKD and baseline albuminuria, or protein in urine, lorundrostat reduced urine albumin-to-creatinine ratio by 52% versus placebo. Confirmed hyperkalemia, or high blood potassium, occurred in 2.4% of CKD participants and 0% without CKD. Lorundrostat is under FDA review for hypertension alongside other blood pressure drugs, with a December 22, 2026 target decision date.
Mineralys Therapeutics (MLYS) expanded its board of directors with the appointments of biopharmaceutical executives Kristine Peterson and Lonnel Coats.
The appointments come ahead of the December 22 PDUFA target action date, the target date for a regulatory decision on lorundrostat. Mineralys is preparing for potential approval and commercial launch for uncontrolled or resistant hypertension.
Peterson most recently served as chief executive officer of Valeritas and previously held leadership positions at Johnson & Johnson, Biovail and Bristol-Myers Squibb. Coats most recently served as chief executive officer of Lexicon Pharmaceuticals and previously held leadership roles at Eisai. Both have more than three decades of experience, including building or leading commercial organizations.
Mineralys Therapeutics (MLYS) presented new lorundrostat trial data showing 46% of treated Launch-HTN participants reached the recommended systolic blood pressure target.
In the pivotal Phase 3 trial, participants receiving 50 mg achieved office systolic blood pressure below 130 mmHg at Week 12; more than two-thirds achieved a reduction of at least 10 mmHg. Final Phase 2 Explore-OSA results in overweight or obese adults with moderate-to-severe obstructive sleep apnea and hypertension showed a morning systolic blood pressure reduction of 11.1 mmHg at Week 4 with 50 mg taken each evening, compared with 1.0 mmHg with placebo. No measurable change in apnea-hypopnea indices, measures of sleep-related breathing disruptions, was observed. Explore-OSA showed no evidence of significant safety events, including high serum potassium.
Mineralys Therapeutics (MLYS) will present new lorundrostat data from Launch-HTN at ASN Kidney Week 2026, taking place October 21–25 in Denver. The oral presentation focuses on blood pressure and albuminuria, or albumin in urine, reduction in chronic kidney disease stages 1 to 3. Launch-HTN was a Phase 3 trial in adults whose blood pressure remained uncontrolled despite two to five antihypertensive medications.